Delving into the Latest Updates on Sun Pharmaceutical Industries (Europe) BV with Synapse

Enzymatic degradation of abundant renewable polysaccharides such as cellulose and starch is a field that has the attention of both the industrial and scientific community. Most of the polysaccharide degrading enzymes are classified into several glycoside hydrolase families. They are often organized in a modular manner which includes a catalytic domain connected to one or more carbohydrate-binding modules. The carbohydrate-binding modules (CBM) have been shown to increase the proximity of the enzyme to its substrate, especially for insoluble substrates. Therefore, these modules are considered to enhance enzymatic hydrolysis. These properties have played an important role in many biotechnological applications with the aim to improve the efficiency of polysaccharide degradation. The domain organization of glycoside hydrolases (GHs) equipped with one or more CBM does vary within organisms. This review comprehensively highlights the presence of CBM as ancillary modules and explores the diversity of GHs carrying one or more of these modules that actively act either on cellulose or starch. Special emphasis is given to the cellulase and amylase distribution within the filamentous microorganisms from the genera of Streptomyces and Aspergillus that are well known to have a great capacity for secreting a wide range of these polysaccharide degrading enzyme. The potential of the CBM and other ancillary domains for the design of improved polysaccharide decomposing enzymes is discussed.

100 项与 Sun Pharmaceutical Industries (Europe) BV 相关的药物交易

登录后查看更多信息

100 项与 Sun Pharmaceutical Industries (Europe) BV 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

9

2

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

左乙拉西坦 ( SV2A )	特发全身性癫痫更多	批准上市
特立帕肽生物类似药(Sun Pharmaceutical Industries Ltd.) ( PTH1R )	绝经期后骨质疏松更多	批准上市
厄他培南钠 ( PBPs )	腹腔感染更多	批准上市
醋酸阿托西班 ( AVPR x OXTR )	早产更多	批准上市
磷酸西格列汀 ( DPP-4 )	2型糖尿病更多	批准上市